Why the study?
Does recombinant human soluble thrombomodulin improve DIC resolution and reduce bleeding compared to heparin in patients with disseminated intravascular coagulation?
Does recombinant human soluble thrombomodulin improve DIC resolution and reduce bleeding compared to heparin in patients with disseminated intravascular coagulation?
Answers are grounded in this paper and cite their sources.
Recombinant human soluble thrombomodulin is an effective and safe treatment for DIC, demonstrating non-inferiority to heparin for DIC resolution while significantly reducing bleeding-related adverse events.
Points(1)汎発性血管内凝固亢進症（DIC）を効能・効果として承認された世界初の組換えヒトトロンボモジュリン製剤である．(2)トロンビンと結合してプロテインCを活性化し，トロンビンの生成を阻害することでDICを改善する．(3)投与は1日1回380U/kgを30分の点滴静注であり非常に簡便である．(4)DICの離脱効果，出血症状の改善，凝血学的検査値の改善，出血症状に関する有害事象発現率において優れている．(5)他の抗凝固剤との併用時の有効性，安全性は明らかではない．
No takes yet. Share an insight, caveat, or question.
Kohji SUZUKI (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: